Towards a paradigm shift in the treatment of chronic Chagas disease

Autores
Viotti, Rodolfo Jorge; Alarcón de Noya, B.; Araujo Jorge, T.; Grijalva, M. J.; Guhl, F.; López, M. C.; Ramsey, J. M.; Ribeiro, I.; Schijman, Alejandro Gabriel; Sosa Estani, S.; Torrico, F.; Gascon, J.
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
Fil: Viotti, Rodolfo Jorge. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Peron"; Argentina
Fil: Alarcón de Noya, B.. Universidad Central de Venezuela. Instituto de Medicina Tropical; Venezuela
Fil: Araujo Jorge, T.. Ministerio de Salud de Brasil. Fundacion Oswaldo Cruz; Brasil
Fil: Grijalva, M. J.. Pontificia Universidad Católica del Ecuador. Centro de Investigación de Enfermedades Infecciosas; Ecuador. Ohio University. Tropical Disease Institute; Estados Unidos
Fil: Guhl, F.. Universidad de los Andes. Centro de Investigaciones en Microbiología y Parasitología Tropical; Colombia
Fil: López, M. C.. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina "Lopez Neyra"; España
Fil: Ramsey, J. M.. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; México
Fil: Ribeiro, I.. Drugs for Neglected Diseases Initiative; Suiza
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; Argentina
Fil: Sosa Estani, S.. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; Argentina
Fil: Torrico, F.. Universidad Mayor de San Simón; Bolivia
Fil: Gascon, J.. Centro de Investigación en Salud Internacional de Barcelona; España
Materia
Chagas disease
Treatment
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/3966
Acceder
id CONICETDig_849b63b1bc8f6222379a469538b93e90
oai_identifier_str oai:ri.conicet.gov.ar:11336/3966
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Towards a paradigm shift in the treatment of chronic Chagas diseaseViotti, Rodolfo JorgeAlarcón de Noya, B.Araujo Jorge, T.Grijalva, M. J.Guhl, F.López, M. C.Ramsey, J. M.Ribeiro, I.Schijman, Alejandro GabrielSosa Estani, S.Torrico, F.Gascon, J.Chagas diseaseTreatmenthttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.Fil: Viotti, Rodolfo Jorge. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Peron"; ArgentinaFil: Alarcón de Noya, B.. Universidad Central de Venezuela. Instituto de Medicina Tropical; VenezuelaFil: Araujo Jorge, T.. Ministerio de Salud de Brasil. Fundacion Oswaldo Cruz; BrasilFil: Grijalva, M. J.. Pontificia Universidad Católica del Ecuador. Centro de Investigación de Enfermedades Infecciosas; Ecuador. Ohio University. Tropical Disease Institute; Estados UnidosFil: Guhl, F.. Universidad de los Andes. Centro de Investigaciones en Microbiología y Parasitología Tropical; ColombiaFil: López, M. C.. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina "Lopez Neyra"; EspañaFil: Ramsey, J. M.. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; MéxicoFil: Ribeiro, I.. Drugs for Neglected Diseases Initiative; SuizaFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; ArgentinaFil: Sosa Estani, S.. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; ArgentinaFil: Torrico, F.. Universidad Mayor de San Simón; BoliviaFil: Gascon, J.. Centro de Investigación en Salud Internacional de Barcelona; EspañaAmerican Society for Microbiology2014-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/3966Viotti, Rodolfo Jorge; Alarcón de Noya, B.; Araujo Jorge, T.; Grijalva, M. J.; Guhl, F.; et al.; Towards a paradigm shift in the treatment of chronic Chagas disease; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 58; 2; 2-2014; 635-6390066-4804enginfo:eu-repo/semantics/altIdentifier/url/http://aac.asm.org/content/58/2/635.fullinfo:eu-repo/semantics/altIdentifier/doi/doi:10.1128/AAC.01662-13info:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910900/info:eu-repo/semantics/altIdentifier/issn/0066-4804info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:38:26Zoai:ri.conicet.gov.ar:11336/3966instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:38:27.129CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Towards a paradigm shift in the treatment of chronic Chagas disease
title Towards a paradigm shift in the treatment of chronic Chagas disease
spellingShingle Towards a paradigm shift in the treatment of chronic Chagas disease
Viotti, Rodolfo Jorge
Chagas disease
Treatment
title_short Towards a paradigm shift in the treatment of chronic Chagas disease
title_full Towards a paradigm shift in the treatment of chronic Chagas disease
title_fullStr Towards a paradigm shift in the treatment of chronic Chagas disease
title_full_unstemmed Towards a paradigm shift in the treatment of chronic Chagas disease
title_sort Towards a paradigm shift in the treatment of chronic Chagas disease
dc.creator.none.fl_str_mv Viotti, Rodolfo Jorge
Alarcón de Noya, B.
Araujo Jorge, T.
Grijalva, M. J.
Guhl, F.
López, M. C.
Ramsey, J. M.
Ribeiro, I.
Schijman, Alejandro Gabriel
Sosa Estani, S.
Torrico, F.
Gascon, J.
author Viotti, Rodolfo Jorge
author_facet Viotti, Rodolfo Jorge
Alarcón de Noya, B.
Araujo Jorge, T.
Grijalva, M. J.
Guhl, F.
López, M. C.
Ramsey, J. M.
Ribeiro, I.
Schijman, Alejandro Gabriel
Sosa Estani, S.
Torrico, F.
Gascon, J.
author_role author
author2 Alarcón de Noya, B.
Araujo Jorge, T.
Grijalva, M. J.
Guhl, F.
López, M. C.
Ramsey, J. M.
Ribeiro, I.
Schijman, Alejandro Gabriel
Sosa Estani, S.
Torrico, F.
Gascon, J.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chagas disease
Treatment
topic Chagas disease
Treatment
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
Fil: Viotti, Rodolfo Jorge. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Peron"; Argentina
Fil: Alarcón de Noya, B.. Universidad Central de Venezuela. Instituto de Medicina Tropical; Venezuela
Fil: Araujo Jorge, T.. Ministerio de Salud de Brasil. Fundacion Oswaldo Cruz; Brasil
Fil: Grijalva, M. J.. Pontificia Universidad Católica del Ecuador. Centro de Investigación de Enfermedades Infecciosas; Ecuador. Ohio University. Tropical Disease Institute; Estados Unidos
Fil: Guhl, F.. Universidad de los Andes. Centro de Investigaciones en Microbiología y Parasitología Tropical; Colombia
Fil: López, M. C.. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina "Lopez Neyra"; España
Fil: Ramsey, J. M.. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; México
Fil: Ribeiro, I.. Drugs for Neglected Diseases Initiative; Suiza
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; Argentina
Fil: Sosa Estani, S.. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; Argentina
Fil: Torrico, F.. Universidad Mayor de San Simón; Bolivia
Fil: Gascon, J.. Centro de Investigación en Salud Internacional de Barcelona; España
description Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
publishDate 2014
dc.date.none.fl_str_mv 2014-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/3966
Viotti, Rodolfo Jorge; Alarcón de Noya, B.; Araujo Jorge, T.; Grijalva, M. J.; Guhl, F.; et al.; Towards a paradigm shift in the treatment of chronic Chagas disease; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 58; 2; 2-2014; 635-639
0066-4804
url http://hdl.handle.net/11336/3966
identifier_str_mv Viotti, Rodolfo Jorge; Alarcón de Noya, B.; Araujo Jorge, T.; Grijalva, M. J.; Guhl, F.; et al.; Towards a paradigm shift in the treatment of chronic Chagas disease; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 58; 2; 2-2014; 635-639
0066-4804
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://aac.asm.org/content/58/2/635.full
info:eu-repo/semantics/altIdentifier/doi/doi:10.1128/AAC.01662-13
info:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910900/
info:eu-repo/semantics/altIdentifier/issn/0066-4804
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614407059931136
score 13.070432

Publicaciones similares